A Trial of Transplanting Hepatitis C-Viremic Kidneys into Hepatitis C-Negative Kidney Recipients (THINKER-NEXT)
Sponsor: |
National Institutes of Health |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT2874 |
U.S. Govt. ID: |
NCT04075916 |
Contact: |
Transplant Clinical Research Center: / tcrcstudyreferral@cumc.columbia.edu |
Kidney transplant extends life, improves quality of life, and reduces healthcare costs. Unfortunately, there are not enough donated kidneys, so many people who need a transplant spend years on the waiting list. Kidneys from organ donors who have hepatitis C virus (HCV) are often thrown away, but these kidneys work well, and hepatitis C can be cured. The goal of the THINKER-NEXT study is to make more kidneys available for transplant. THINKER-NEXT is a study that will provide HCV infected kidneys to people on the kidney transplant waiting list who do not have hepatitis C. We will then cure the HCV infection with an antiviral drug. For more information you can also visit https://www.thinkernextstudy.org/. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Investigator
Elizabeth Verna, MD
Are you you at least 18 years old? |
Yes |
No |
Are you on the waiting list for kidney transplant? |
Yes |
No |